Equities Analysts Set Expectations for Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG - Free Report) - Research analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for shares of Neogen in a research note issued on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company will earn $0.12 per share for the quarter, down from their prior forecast of $0.14. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q4 2025 earnings at $0.13 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.52 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its quarterly earnings results on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm had revenue of $231.30 million for the quarter, compared to analysts' expectations of $227.16 million. During the same quarter in the prior year, the firm earned $0.11 EPS. The business's revenue for the quarter was up .7% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the company. Piper Sandler reaffirmed a "neutral" rating and set a $13.00 price target (down previously from $16.50) on shares of Neogen in a research report on Tuesday, January 21st. Guggenheim began coverage on Neogen in a report on Thursday, December 19th. They set a "buy" rating and a $15.00 price objective on the stock.

Neogen Stock Performance

Shares of NASDAQ NEOG traded down $0.52 during trading on Thursday, reaching $10.94. 2,718,789 shares of the stock traded hands, compared to its average volume of 3,042,747. Neogen has a 52-week low of $10.72 and a 52-week high of $18.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. The company has a 50-day moving average of $12.45 and a 200-day moving average of $14.63. The stock has a market capitalization of $2.37 billion, a P/E ratio of -5.00 and a beta of 1.23.

Hedge Funds Weigh In On Neogen

A number of institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC increased its position in shares of Neogen by 142.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company's stock valued at $33,000 after purchasing an additional 1,165 shares during the last quarter. Blue Trust Inc. increased its position in shares of Neogen by 196.7% during the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company's stock valued at $41,000 after purchasing an additional 2,233 shares during the last quarter. Neo Ivy Capital Management bought a new position in shares of Neogen during the 3rd quarter valued at about $66,000. KBC Group NV increased its position in shares of Neogen by 39.1% during the 4th quarter. KBC Group NV now owns 8,464 shares of the company's stock valued at $103,000 after purchasing an additional 2,379 shares during the last quarter. Finally, Hardy Reed LLC bought a new position in shares of Neogen during the 4th quarter valued at about $133,000. 96.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Neogen news, CFO David H. Naemura bought 14,800 shares of the firm's stock in a transaction on Thursday, January 16th. The shares were acquired at an average cost of $11.11 per share, for a total transaction of $164,428.00. Following the purchase, the chief financial officer now directly owns 61,434 shares of the company's stock, valued at $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Edward Adent bought 23,035 shares of the firm's stock in a transaction on Thursday, January 16th. The stock was acquired at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the purchase, the chief executive officer now directly owns 269,164 shares in the company, valued at approximately $2,968,878.92. The trade was a 9.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by insiders.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.